DNMT1 Transition State Inhibitors for Non-Mutagenic Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNMT inhibitors used in cancer therapy, such as 5-aza-cytidine and 5-aza-deoxycytidine, are mutagenic and cause genomic mutations due to their incorporation into DNA, necessitating the development of new inhibitors that target human DNA methyltransferase 1 (DNMT1) effectively without mutagenic effects.
Innovation Solution
Designing and obtaining compounds that resemble the charge and geometry of the DNMT1 transition state (TS) using a computer-implemented, experimentally-guided kinetic isotope effect method, which involves designing chemically stable compounds that mimic the molecular electrostatic potential and geometric atomic volume of the DNMT1 TS to inhibit DNMT1 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNMT inhibitors (5-aza-cytidine, 5-aza-deoxycytidine) are used to target DNMT1, then DNMT1 inhibition is achieved, but mutagenic effects and genomic mutations occur due to DNA incorporation
Solution Approach 1:
The patent creates transition state analog inhibitors that copy the geometry and charge distribution of the DNMT1 transition state rather than copying natural DNA bases. This copying approach produces compounds that bind tightly to DNMT1's active site while lacking the properties that cause mutagenic DNA incorporation, thus achieving reliable DNMT1 inhibition without harmful mutagenic effects
Solution Approach 2:
The transition state structure serves as an intermediary model that bridges the gap between substrate binding and product formation. By designing inhibitors based on this intermediary transition state structure, the patent achieves strong enzyme inhibition while avoiding the direct DNA incorporation mechanism that causes mutagenesis in traditional azacytidine-based inhibitors
2Object-affected harmful factors
If transition state analog compounds are designed to resemble DNMT1 transition state charge and geometry, then specific DNMT1 inhibition is achieved without mutagenic effects, but compound design complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular geometry and charge distribution parameters to optimize transition state analog structures. By focusing on key parameters such as the pentavalent carbon geometry, bond lengths, and charge distribution patterns characteristic of the DNMT1 transition state, the design process becomes more directed and less complex than random screening approaches
Solution Approach 2:
The complex task of designing transition state analogs is segmented into manageable components: first determining the transition state geometry through kinetic isotope effect measurements, then separately optimizing different molecular regions to match specific geometric and electrostatic features, and finally assembling these segments into complete inhibitor molecules with desired properties
Data Source
AI summary
Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.